Multi-Tracer PET-Guided Therapy Selection and Theranostics in Radioiodine-Refractory Thyroid Cancer Patient Unsuitable for Tyrosine Kinase Inhibitor Therapy.

IF 1 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING World Journal of Nuclear Medicine Pub Date : 2025-10-04 eCollection Date: 2026-09-01 DOI:10.1055/s-0045-1812056

Austin Saju, Sunita Sonavane, Sandip Basu

{"title":"Multi-Tracer PET-Guided Therapy Selection and Theranostics in Radioiodine-Refractory Thyroid Cancer Patient Unsuitable for Tyrosine Kinase Inhibitor Therapy.","authors":"Austin Saju, Sunita Sonavane, Sandip Basu","doi":"10.1055/s-0045-1812056","DOIUrl":null,"url":null,"abstract":"Radioactive iodine refractory (RAIR) thyroid cancer and thyroglobulin elevated negative iodine scintigraphy constitute a fraction of thyroid cancer patients with poorer prognosis as opposed to radioiodine concentrating disease. Although not a rare condition and with several treatment options already explored, the selection of an optimal therapy that balances effective disease stabilization, symptom palliation, life prolongation, and minimal side effects remains essential. The use of multi-tracer positron emission tomography (PET) shows potential for radionuclide therapy selection in RAIR thyroid cancer. In this case report, multi-tracer PET imaging was employed to assess the feasibility of available theranostic options. While [ 68 Ga]Ga-DOTATATE PET/computed tomography (CT) showed low-level somatostatin receptor expression, [ 68 Ga]Ga-prostate specific membrane antigen (PSMA)-11 PET/CT revealed moderate and concordant PSMA expression across all lesions observed on [ 18 F]F-FDG PET/CT, justifying [ 177 Lu]Lu-PSMA-617 therapy in this patient.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"266-270"},"PeriodicalIF":1.0000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0045-1812056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Radioactive iodine refractory (RAIR) thyroid cancer and thyroglobulin elevated negative iodine scintigraphy constitute a fraction of thyroid cancer patients with poorer prognosis as opposed to radioiodine concentrating disease. Although not a rare condition and with several treatment options already explored, the selection of an optimal therapy that balances effective disease stabilization, symptom palliation, life prolongation, and minimal side effects remains essential. The use of multi-tracer positron emission tomography (PET) shows potential for radionuclide therapy selection in RAIR thyroid cancer. In this case report, multi-tracer PET imaging was employed to assess the feasibility of available theranostic options. While [ ⁶⁸ Ga]Ga-DOTATATE PET/computed tomography (CT) showed low-level somatostatin receptor expression, [ ⁶⁸ Ga]Ga-prostate specific membrane antigen (PSMA)-11 PET/CT revealed moderate and concordant PSMA expression across all lesions observed on [ ¹⁸ F]F-FDG PET/CT, justifying [ ¹⁷⁷ Lu]Lu-PSMA-617 therapy in this patient.

查看原文